logo
Plus   Neg
Share
Email

Pfizer Updates On EMA Application For SUTENT

Pfizer Inc. (PFE) announced that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency or EMA has recommended against expanding use of SUTENT or sunitinib to include the adjuvant treatment of adult patients at a high risk of recurrent renal cell carcinoma or RCC following nephrectomy (surgical removal of the cancerous kidney).

The CHMP's recommendation is not binding but will now be taken into consideration by the European Commission. There is currently no approved adjuvant treatment option available for patients with non-metastatic RCC at high risk for recurrence in the European Union.

In the U.S., SUTENT is approved for the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The National Labor Relations Board ruled in favor of McDonald's in a long-running case filed by workers who accused the fast-food giant of retaliation after they tried to unionize. The lawsuit, filed by 20 employees against McDonald's and some of its franchise operators in 2015. The lawsuit was seeking a ruling that would consider McDonald's a 'joint employer' with its franchisees. Shares of Facebook fell almost 3 percent in Thursday's trading after the Wall Street Journal reported that the Federal Trade Commission is considering seeking a preliminary injunction against Facebook amid antitrust concerns over the company's integration of its apps. Facebook had earlier said it was planning to integrate its three messaging services. Beverages giant Pepsi announced the launch Pepsi Café, a new coffee-infused cola, which will debut in the United States in April 2020. The new beverage, which aims to satisfy both cola lovers and coffee fanatics across the US, comes in two delicious flavors - Original and Vanilla, with roasted Arabica coffee. It will be available at all major national retailers beginning in April next year.
Follow RTT
>